TG2 as a novel breast cancer prognostic marker promotes cell proliferation and glycolysis by activating the MEK/ERK/LDH pathway

Table 1 Correlation between clinicopathological characteristics and TG2 expression in breast cancer samples

Characteristics	*TG2* Expression		χ2	P value
Characteristics	0–1+	2–3+	χ2	P value
Age (year)
<50	43	61
≥ 50	41	65	0.156	0.693
Menopause
No	47	65
Yes	37	61	0.386	0.534
MBNG
1	7	10
2	57	94
3	20	22	1.345	0.511
Clinical stage
I	44	40
II	25	52
III	15	34	8.985	0.011
T stage
1	56	76
2	26	43
3	2	6
4	0	1	1.894	0.595
N stage
0	50	64
1	19	31
2	9	17
3	6	14	1.938	0.585
ER
Negative	17	30
Positive	67	96	0.370	0.543
PR status
Negative	24	34
Positive	60	92	0.064	0.801
Her-2
Negative	41	64
1+	19	20
2+	19	29
3+	5	13	2.399	0.494
Ki-67
<30%	59	87
≥ 30%	25	39	1.523	0.467
Molecular subtype
Luminal A	21	51
Luminal B (Her-2-)	12	33
Luminal B (Her-2+)	32	14
Her-2+	8	15
Basal like	8	13	22.098	<0.001
Survival
Yes	80	99
No	4	27	17.864	<0.001

ISSN: 1471-2407